Investigación
Educación
Iniciar sesión
ES
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Medical Genetics
Kelly A. Avery-Kiejda has not added Biography.
If you are Kelly A. Avery-Kiejda and would like to personalize this page please email our Author Liaison for assistance.
Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells.
Anti-cancer drugs Feb, 2008 | Pubmed ID: 18176116
Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research Mar, 2008 | Pubmed ID: 18310316
Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress.
Cancer research Aug, 2008 | Pubmed ID: 18701495
Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells.
Carcinogenesis Feb, 2009 | Pubmed ID: 18842681
Nucleotide excision repair gene expression after Cisplatin treatment in melanoma.
Cancer research Oct, 2010 | Pubmed ID: 20807809
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Breast cancer research and treatment Jun, 2011 | Pubmed ID: 21409391
P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation.
BMC cancer , 2011 | Pubmed ID: 21615965
Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
International journal of cancer Jan, 2014 | Pubmed ID: 23824750
Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
PloS one , 2013 | Pubmed ID: 23940574
STaRRRT: a table of short tandem repeats in regulatory regions of the human genome.
BMC genomics , 2013 | Pubmed ID: 24228761
The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.
Carcinogenesis Mar, 2014 | Pubmed ID: 24336193
Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer.
BMC cancer , 2014 | Pubmed ID: 24479446
The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer.
BMC cancer , 2014 | Pubmed ID: 24725360
Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value.
Nature communications , 2015 | Pubmed ID: 25641231
Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis.
Molecular & cellular proteomics : MCP Sep, 2015 | Pubmed ID: 26041846
Novel genes associated with lymph node metastasis in triple negative breast cancer.
Scientific reports , 2015 | Pubmed ID: 26537449
The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low Δ40p53:p53 ratio and better outcome.
Carcinogenesis Jan, 2016 | Pubmed ID: 26586794
MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer.
International journal of molecular sciences , 2015 | Pubmed ID: 26633365
A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer.
Endocrine connections May, 2016 | Pubmed ID: 27090263
A novel polymorphic repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is not associated with the risk of developing breast or endometrial cancer.
BMC research notes , 2016 | Pubmed ID: 27230222
The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer.
Breast cancer research and treatment Nov, 2018 | Pubmed ID: 30430302
Hunter Medical Research Institute
University of Newcastle
Brianna C. Morten1,2,
Rodney J. Scott1,2,3,
Kelly A. Avery-Kiejda1,2
1Medical Genetics, Hunter Medical Research Institute,
2Priority Research Centre for Cancer, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle,
3Pathology North, John Hunter Hospital
Xiajie Zhang1,2,
2Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle,
Privacidad
Condiciones de uso
Políticas
Contáctenos
RECOMIENDE A LA BIBLIOTECA
BOLETINES de JoVE
JoVE Journal
Colecciones de métodos
JoVE Encyclopedia of Experiments
Archivo
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centro de recursos académicos
Autores
Bibliotecarios
Acceso
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados